Arbutus Biopharma Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M |
| Research and development | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M |
| Operating expenses | $52.2M | $82.5M | $96.2M | $104.5M | $84.5M |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M |
| Interest expense | $97,000 | $137,000 | $459,000 | $1.7M | $2.9M |
| Income tax expense | $0 | $0 | $0 | $4.4M | $0 |
| Net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M | -$76.2M |
| Balance Sheet | |||||
| Cash and equivalents | $18.0M | $36.3M | $26.3M | $30.8M | $109.3M |
| Current assets | $94.5M | $127.3M | $132.0M | $151.1M | $160.7M |
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M |
| Current liabilities | $6.0M | $15.6M | $22.5M | $32.9M | $11.2M |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M |
| Stockholders' equity | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M |
| Depreciation and amortization | $363,000 | $1.4M | $1.4M | $1.4M | $1.8M |
| Stock-based compensation | $7.0M | $9.0M | $9.3M | $7.2M | $6.4M |
| Capital expenditure | $0 | $182,000 | $1.0M | $512,000 | $809,000 |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M |
Shares outstanding 197.5M · Free float 52.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.